Lipase: Difference between revisions
Ostermayer (talk | contribs) (Created page with "'''Lipase''' is a pancreatic enzyme that hydrolyzes triglycerides into glycerol and free fatty acids. Serum lipase is the preferred biomarker for the diagnosis of acute pancreatitis in the emergency department, offering superior sensitivity and a wider diagnostic window compared to amylase.<ref>Cartier T, Sogni P, Perruche F, et al. Normal lipase serum level in acute pancreatitis: is it an early or late determination? ''Emerg Med J''. 2011;28(11):997...") |
(Formatting: moved intro to Background bullets, removed excessive bold from bullet lead-ins) |
||
| Line 1: | Line 1: | ||
==Background== | |||
*Lipase is a pancreatic enzyme that hydrolyzes triglycerides into glycerol and free fatty acids. | |||
*Serum lipase is the preferred biomarker for the diagnosis of [[Pancreatitis|acute pancreatitis]] in the emergency department, offering superior sensitivity and a wider diagnostic window compared to [[amylase]].<ref>Cartier T, Sogni P, Perruche F, et al. | |||
*Normal lipase serum level in acute pancreatitis: is it an early or late determination? ''Emerg Med J''. 2011;28(11):997-998.</ref> | |||
* Lipase is primarily produced by pancreatic acinar cells; smaller amounts are produced by the liver, intestinal mucosa, and other tissues | * Lipase is primarily produced by pancreatic acinar cells; smaller amounts are produced by the liver, intestinal mucosa, and other tissues | ||
* Normal reference range is approximately 0-160 U/L (varies by assay and institution) | * Normal reference range is approximately 0-160 U/L (varies by assay and institution) | ||
| Line 7: | Line 10: | ||
==Diagnostic threshold== | ==Diagnostic threshold== | ||
* | * ≥3 times the upper limit of normal (ULN) is the accepted diagnostic cutoff for [[Pancreatitis|acute pancreatitis]] | ||
** At this threshold: sensitivity 80-100%, specificity 95-99%<ref>Sternby B, O'Brien JF, Zinsmeister AR, DiMagno EP. What is the best biochemical test to diagnose acute pancreatitis? A prospective clinical study. ''Mayo Clin Proc''. 1996;71(12):1138-1144.</ref> | ** At this threshold: sensitivity 80-100%, specificity 95-99%<ref>Sternby B, O'Brien JF, Zinsmeister AR, DiMagno EP. What is the best biochemical test to diagnose acute pancreatitis? A prospective clinical study. ''Mayo Clin Proc''. 1996;71(12):1138-1144.</ref> | ||
* Rises within 3-6 hours of symptom onset | * Rises within 3-6 hours of symptom onset | ||
* Peaks at 24-48 hours | * Peaks at 24-48 hours | ||
* Remains elevated for 7-14 days (longer than amylase, which normalizes within 3-5 days) | * Remains elevated for 7-14 days (longer than amylase, which normalizes within 3-5 days) | ||
* | * A normal lipase does not completely exclude acute pancreatitis, particularly in recurrent or chronic disease | ||
==Interpretation== | ==Interpretation== | ||
| Line 28: | Line 31: | ||
===Non-pancreatic causes of elevated lipase=== | ===Non-pancreatic causes of elevated lipase=== | ||
* | * Reduced clearance: | ||
** [[Renal failure]] / [[Acute kidney injury|AKI]] (most common non-pancreatic cause; incidence 14-80% in renal failure)<ref>Manjuck J, Zein J, Ghai V, et al. Nonpancreatic causes of significantly elevated serum lipase in the ICU: a systematic review. ''HPB''. 2015;17(3):195-199.</ref> | ** [[Renal failure]] / [[Acute kidney injury|AKI]] (most common non-pancreatic cause; incidence 14-80% in renal failure)<ref>Manjuck J, Zein J, Ghai V, et al. Nonpancreatic causes of significantly elevated serum lipase in the ICU: a systematic review. ''HPB''. 2015;17(3):195-199.</ref> | ||
** Macrolipasemia (lipase-immunoglobulin complexes) | ** Macrolipasemia (lipase-immunoglobulin complexes) | ||
* | * Intra-abdominal pathology: | ||
** [[Cholecystitis]], [[choledocholithiasis]] | ** [[Cholecystitis]], [[choledocholithiasis]] | ||
** [[Small bowel obstruction]] | ** [[Small bowel obstruction]] | ||
| Line 39: | Line 42: | ||
** [[Inflammatory bowel disease]] | ** [[Inflammatory bowel disease]] | ||
** Pancreatic or periampullary malignancy | ** Pancreatic or periampullary malignancy | ||
* | * Metabolic: | ||
** [[Diabetic ketoacidosis]] (may elevate lipase >3x ULN without pancreatitis) | ** [[Diabetic ketoacidosis]] (may elevate lipase >3x ULN without pancreatitis) | ||
** [[Hypertriglyceridemia]] | ** [[Hypertriglyceridemia]] | ||
* | * Other: | ||
** [[Sepsis]] / critical illness | ** [[Sepsis]] / critical illness | ||
** Intracranial hemorrhage / neurosurgical pathology | ** Intracranial hemorrhage / neurosurgical pathology | ||
| Line 51: | Line 54: | ||
==Pearls== | ==Pearls== | ||
* | * Lipase alone is sufficient — co-ordering amylase with lipase does not improve diagnostic accuracy and adds unnecessary cost<ref>Moridani MY, Bromberg IL. Lipase and pancreatic amylase versus total amylase as biomarkers of pancreatitis: an analytical investigation. ''Clin Biochem''. 2003;36(1):31-33.</ref> | ||
* '''Do not trend lipase''' — serial monitoring is unnecessary and does not predict severity, complications, or guide management<ref>Tenner S, Baillie J, DeWitt J, Vege SS. American College of Gastroenterology guideline: management of acute pancreatitis. ''Am J Gastroenterol''. 2013;108(9):1400-1415.</ref> | * '''Do not trend lipase''' — serial monitoring is unnecessary and does not predict severity, complications, or guide management<ref>Tenner S, Baillie J, DeWitt J, Vege SS. American College of Gastroenterology guideline: management of acute pancreatitis. ''Am J Gastroenterol''. 2013;108(9):1400-1415.</ref> | ||
* Degree of lipase elevation does '''not''' correlate with disease severity in adults | * Degree of lipase elevation does '''not''' correlate with disease severity in adults | ||
Latest revision as of 15:56, 19 March 2026
Background
- Lipase is a pancreatic enzyme that hydrolyzes triglycerides into glycerol and free fatty acids.
- Serum lipase is the preferred biomarker for the diagnosis of acute pancreatitis in the emergency department, offering superior sensitivity and a wider diagnostic window compared to amylase.[1]
- Lipase is primarily produced by pancreatic acinar cells; smaller amounts are produced by the liver, intestinal mucosa, and other tissues
- Normal reference range is approximately 0-160 U/L (varies by assay and institution)
- Preferred over amylase for diagnosis of acute pancreatitis per ACG, AGA, and IAP guidelines[2]
Diagnostic threshold
- ≥3 times the upper limit of normal (ULN) is the accepted diagnostic cutoff for acute pancreatitis
- At this threshold: sensitivity 80-100%, specificity 95-99%[3]
- Rises within 3-6 hours of symptom onset
- Peaks at 24-48 hours
- Remains elevated for 7-14 days (longer than amylase, which normalizes within 3-5 days)
- A normal lipase does not completely exclude acute pancreatitis, particularly in recurrent or chronic disease
Interpretation
Lipase ≥3x ULN
- Highly suggestive of acute pancreatitis when combined with compatible clinical presentation
- Diagnosis of acute pancreatitis requires ≥2 of 3 criteria:[4]
- Characteristic abdominal pain (epigastric, radiating to back)
- Serum lipase (or amylase) ≥3x ULN
- Characteristic findings on imaging (CT, MRI, or ultrasound)
Lipase <3x ULN but elevated
- Non-specific; consider both pancreatic and non-pancreatic causes
- Abdominal imaging advised if associated with abdominal pain
Non-pancreatic causes of elevated lipase
- Reduced clearance:
- Renal failure / AKI (most common non-pancreatic cause; incidence 14-80% in renal failure)[5]
- Macrolipasemia (lipase-immunoglobulin complexes)
- Intra-abdominal pathology:
- Cholecystitis, choledocholithiasis
- Small bowel obstruction
- Mesenteric ischemia / intestinal infarction
- Peptic ulcer disease / perforated viscus
- Appendicitis
- Inflammatory bowel disease
- Pancreatic or periampullary malignancy
- Metabolic:
- Diabetic ketoacidosis (may elevate lipase >3x ULN without pancreatitis)
- Hypertriglyceridemia
- Other:
Pearls
- Lipase alone is sufficient — co-ordering amylase with lipase does not improve diagnostic accuracy and adds unnecessary cost[6]
- Do not trend lipase — serial monitoring is unnecessary and does not predict severity, complications, or guide management[7]
- Degree of lipase elevation does not correlate with disease severity in adults
- Lipase has a wider diagnostic window than amylase, making it more useful in patients with delayed presentations (>24-48 hours after symptom onset)
- In hypertriglyceridemic pancreatitis, lipase may be falsely normal due to assay interference; if clinical suspicion is high, treat empirically
- Consider non-pancreatic causes when lipase is elevated but clinical features are not consistent with pancreatitis, especially in patients with renal failure or DKA
- If the diagnosis remains uncertain, CT abdomen with IV contrast is recommended ≥72 hours after symptom onset for optimal sensitivity in detecting necrosis
See Also
External Links
References
- ↑ Cartier T, Sogni P, Perruche F, et al.
- Normal lipase serum level in acute pancreatitis: is it an early or late determination? Emerg Med J. 2011;28(11):997-998.
- ↑ Tenner S, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9):1400-1415.
- ↑ Sternby B, O'Brien JF, Zinsmeister AR, DiMagno EP. What is the best biochemical test to diagnose acute pancreatitis? A prospective clinical study. Mayo Clin Proc. 1996;71(12):1138-1144.
- ↑ Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis — 2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102-111.
- ↑ Manjuck J, Zein J, Ghai V, et al. Nonpancreatic causes of significantly elevated serum lipase in the ICU: a systematic review. HPB. 2015;17(3):195-199.
- ↑ Moridani MY, Bromberg IL. Lipase and pancreatic amylase versus total amylase as biomarkers of pancreatitis: an analytical investigation. Clin Biochem. 2003;36(1):31-33.
- ↑ Tenner S, Baillie J, DeWitt J, Vege SS. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9):1400-1415.
